New injection fights head and neck cancer from the inside

NCT ID NCT06736379

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new treatment called VLPONC-01, which is injected directly into head and neck tumors. It delivers a substance (IL-12) that may help the immune system attack the cancer. Some participants will also receive the immunotherapy drug pembrolizumab. The main goal is to check safety and see if the tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
VLPONC-01 (a virus-based therapy that delivers IL-12 into tumors) and pembrolizumab (an immunotherapy drug)
What this could lead to
If successful, this could point toward a new treatment option for head and neck cancer that boosts the immune system to fight tumors.
What could go wrong
This is a very early (Phase 1) trial with only 41 participants, so safety and effectiveness are not yet proven. There is a risk of side effects from the injections or the combination therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma Mouth Neoplasms oral cavity carcinoma squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Stanford University

    RECRUITING

    Stanford, California, 34305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.